GRCE CIK: 1444192

Grace Therapeutics, Inc.

  • United States
  • Healthcare
  • Biotech
Metrics score locked — part of Premium
FY22
FY23
FY24
FY25
FY26
FY22 – FY26

Assets

(positive)
Change from FY22 to FY26
millions USD
FY22:
45.3
FY23:
29.3
FY24:
24.0
FY25:
22.7
FY26:
17.4
(positive)
Change from FY22 to FY26
millions USD
FY22:
83.3
FY23:
49.8
FY24:
49.3
FY25:
49.3
FY26:
49.3
Total assets
Change from FY22 to FY26
millions USD
FY22:
129
FY23:
79.1
FY24:
73.3
FY25:
72.0
FY26:
66.7

Liabilities & Equity

(negative)
Change from FY22 to FY26
millions USD
FY22:
3.26
FY23:
3.41
FY24:
1.68
FY25:
1.93
FY26:
2.15
(negative)
Change from FY22 to FY26
millions USD
FY22:
17.1
FY23:
7.76
FY24:
9.87
FY25:
3.45
FY26:
0.61
(positive)
Change from FY22 to FY26
millions USD
FY22:
108
FY23:
68.0
FY24:
61.7
FY25:
66.6
FY26:
63.9
Total liabilities & equity
Change from FY22 to FY26
millions USD
FY22:
129
FY23:
79.1
FY24:
73.3
FY25:
72.0
FY26:
66.7

All amounts in millions USD Data source:SEC EDGAR